TIRZEPATIDE — Advanced Dual GIP & GLP-1 Receptor Agonist

Metabolic Research | Glucose Regulation | Weight Management | Incretin-Based Therapy

Product Overview

Tirzepatide is a synthetic peptide and dual GIP/GLP-1 receptor agonist developed by Eli Lilly and marketed under the brand name Mounjaro®.

It is an approved once-weekly injectable prescription medication in Portugal and the European Union for the treatment of type 2 diabetes and weight management in eligible patients with obesity or overweight accompanied by weight-related health conditions.

Tirzepatide simultaneously activates two important metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Through this dual mechanism, tirzepatide influences insulin secretion, appetite regulation, satiety, and energy intake, making it an important subject of metabolic and pharmaceutical research.

Mechanism of Action

• GIP Receptor Activation: Enhances glucose-dependent insulin secretion and contributes to metabolic regulation.

• GLP-1 Receptor Activation: Promotes satiety, reduces appetite, and influences gastric emptying.

• Glucose Homeostasis: Supports blood glucose regulation through incretin-related mechanisms.

• Body Weight Regulation: Reduces food intake through effects on appetite and satiety, contributing to weight reduction in clinical studies.

• Metabolic Research: Provides opportunities to investigate the interaction between incretin signaling, insulin function, and energy balance.

Clinical Research & Scientific Evidence

Clinical trials have demonstrated significant reductions in body weight and improvements in glycemic control in selected patient populations.

Research areas include:

• Type 2 Diabetes: Glycemic control and glucose-dependent insulin responses.

• Obesity & Weight Management: Body weight reduction and long-term metabolic outcomes.

• Appetite Regulation: Hormonal pathways involved in hunger and satiety.

• Metabolic Homeostasis: Interactions between energy intake, glucose regulation, and insulin sensitivity.

• Cardiometabolic Health: Investigation of obesity-related metabolic complications.

Clinical outcomes depend on the population studied, treatment duration, and other individual factors.

Regulatory Status & Safety

Tirzepatide is an approved prescription medication, but research-grade tirzepatide preparations are not automatically approved medicines.

Common adverse reactions associated with approved tirzepatide treatment include nausea, diarrhea, vomiting, constipation, and abdominal discomfort.

More serious risks and precautions require medical assessment and are described in the official prescribing information.

The quality, purity, safety, and effectiveness of independently manufactured research preparations cannot be assumed equivalent to those of authorized pharmaceutical products.

Research Use Only

FOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.

Intended exclusively for qualified professionals conducting legitimate scientific investigations.

Research-grade preparations are not intended for human or veterinary administration, personal injection, self-medication, or unauthorized therapeutic use.

The designation “Research Use Only” does not constitute authorization to manufacture, market, distribute, or administer an unapproved medicinal preparation.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.